Erminia Manfrin

Summary

Affiliation: University of Verona
Country: Italy

Publications

  1. ncbi Intra-operative frozen section technique for breast cancer: end of an era
    E Manfrin
    Department of Pathology and Diagnosis, Section of Surgical Pathology, G B Rossi Hospital, University of Verona, Italy
    Pathologica 103:325-30. 2011
  2. ncbi Risk of neoplastic transformation in asymptomatic radial scar. Analysis of 117 cases
    Erminia Manfrin
    Department of Pathology, University of Verona, Strada Le Grazie 8, 37135, Verona, Italy
    Breast Cancer Res Treat 107:371-7. 2008
  3. ncbi Is there still a role for fine-needle aspiration cytology in breast cancer screening? Experience of the Verona Mammographic Breast Cancer Screening Program with real-time integrated radiopathologic activity (1999-2004)
    Erminia Manfrin
    Department of Pathology, Institute of Pathological Anatomy, University of Verona, Verona, Italy
    Cancer 114:74-82. 2008
  4. ncbi Benign breast lesions at risk of developing cancer--a challenging problem in breast cancer screening programs: five years' experience of the Breast Cancer Screening Program in Verona (1999-2004)
    Erminia Manfrin
    Department of Pathology, University of Verona, Verona, Italy
    Cancer 115:499-507. 2009
  5. ncbi Cancer size, histotype, and cellular grade may limit the success of fine-needle aspiration cytology for screen-detected breast carcinoma
    Erminia Manfrin
    Institute of Pathology, Department of Pathology, University of Verona, Verona, Italy
    Cancer 117:491-9. 2009
  6. ncbi Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria
    Matteo Brunelli
    Anatomic Pathology, Department of Pathology, University of Verona, Verona, Italy
    Am J Clin Pathol 131:678-82. 2009
  7. ncbi Her-2/neu evaluation in Sister Mary Joseph's nodule from breast carcinoma: a case report and review of the literature
    Matteo Brunelli
    Department of Pathology, University of Verona, Verona, Italy
    J Cutan Pathol 36:702-5. 2009
  8. ncbi FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma
    Eleonora Brunello
    Department of Pathology and Diagnostic, University of Verona, P, le Ludovico Scuro n, 10, Verona, 37134, Italy
    J Exp Clin Cancer Res 31:103. 2012
  9. ncbi Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies
    Eleonora Brunello
    Department of Pathology and Diagnostic, University of Verona, Italy
    Histopathology 60:482-8. 2012
  10. ncbi HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy
    Matteo Brunelli
    Department of Pathology, Universita di Verona, Verona, Italy
    Am J Clin Pathol 129:907-11. 2008

Collaborators

Detail Information

Publications13

  1. ncbi Intra-operative frozen section technique for breast cancer: end of an era
    E Manfrin
    Department of Pathology and Diagnosis, Section of Surgical Pathology, G B Rossi Hospital, University of Verona, Italy
    Pathologica 103:325-30. 2011
    ....
  2. ncbi Risk of neoplastic transformation in asymptomatic radial scar. Analysis of 117 cases
    Erminia Manfrin
    Department of Pathology, University of Verona, Strada Le Grazie 8, 37135, Verona, Italy
    Breast Cancer Res Treat 107:371-7. 2008
    ..Previous studies have shown that patient age and the size of RS are correlated to a potential neoplastic transformation...
  3. ncbi Is there still a role for fine-needle aspiration cytology in breast cancer screening? Experience of the Verona Mammographic Breast Cancer Screening Program with real-time integrated radiopathologic activity (1999-2004)
    Erminia Manfrin
    Department of Pathology, Institute of Pathological Anatomy, University of Verona, Verona, Italy
    Cancer 114:74-82. 2008
  4. ncbi Benign breast lesions at risk of developing cancer--a challenging problem in breast cancer screening programs: five years' experience of the Breast Cancer Screening Program in Verona (1999-2004)
    Erminia Manfrin
    Department of Pathology, University of Verona, Verona, Italy
    Cancer 115:499-507. 2009
    ..The authors of this report evaluated the impact of the screen-detected BBL at risk of developing cancer that were counted in the quota of benign breast open biopsies in the Breast Cancer Screening Program of Verona...
  5. ncbi Cancer size, histotype, and cellular grade may limit the success of fine-needle aspiration cytology for screen-detected breast carcinoma
    Erminia Manfrin
    Institute of Pathology, Department of Pathology, University of Verona, Verona, Italy
    Cancer 117:491-9. 2009
    ..The radiological and pathological factors relating to the success of FNAC in breast cancer series were evaluated...
  6. ncbi Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria
    Matteo Brunelli
    Anatomic Pathology, Department of Pathology, University of Verona, Verona, Italy
    Am J Clin Pathol 131:678-82. 2009
    ..The clinical relevance and impact on treatment outcome of intratumoral heterogeneity in breast cancer with low-grade HER2/neu amplification or chromosome 17 polysomy need further investigation...
  7. ncbi Her-2/neu evaluation in Sister Mary Joseph's nodule from breast carcinoma: a case report and review of the literature
    Matteo Brunelli
    Department of Pathology, University of Verona, Verona, Italy
    J Cutan Pathol 36:702-5. 2009
    ....
  8. ncbi FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma
    Eleonora Brunello
    Department of Pathology and Diagnostic, University of Verona, P, le Ludovico Scuro n, 10, Verona, 37134, Italy
    J Exp Clin Cancer Res 31:103. 2012
    ..abstract:..
  9. ncbi Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies
    Eleonora Brunello
    Department of Pathology and Diagnostic, University of Verona, Italy
    Histopathology 60:482-8. 2012
    ..There is consistent lack of data focusing the topoisomerase-IIα gene status in lobular breast carcinoma, a subtype that usually shows poor responsiveness to chemotherapies including those using anthracycline drugs...
  10. ncbi HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy
    Matteo Brunelli
    Department of Pathology, Universita di Verona, Verona, Italy
    Am J Clin Pathol 129:907-11. 2008
    ..The ASCO/CAP scheme has a great concordance coefficient between strong 3+ immunohistochemical cases and cases with high-grade, granular HER-2/neu amplification...
  11. ncbi Occult inflammatory breast cancer: review of clinical, mammographic, US and pathologic signs
    Francesca Caumo
    Dipartimento di Scienze Morfologico Biomediche, Sezione di Radiologia, Policlinico G B Rossi, Verona, Italy
    Radiol Med 109:308-20. 2005
    ..To examine the clinical, radiologic and pathologic findings of occult inflammatory breast cancer (OIBC) in order to identify features useful for diagnosis...
  12. ncbi Rhabdoid carcinoma of the colon: a distinct entity with a very aggressive behavior: a case report associated with a polyposis coli and review of the literature
    Andrea Remo
    Department of Pathology, Mater Salutis Hospital, ULSS 21 Legnago, Verona, Italy
    Int J Surg Pathol 20:185-90. 2012
    ..It is argued that RCT could be a very aggressive entity of colon, which could benefit from new biological colonic treatments...
  13. ncbi Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss
    Giuseppe Bogina
    Department of Pathology, Sacro Cuore Hospital of Negrar, Verona, Italy
    Virchows Arch 459:1-10. 2011
    ..Progesterone receptor loss seems to be influenced by therapy and to correlate with a worse prognosis...